Michelle Arias-Borrero
Surgical · Brewster, NYNPI 1043248057
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 497 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 40 manufacturers, the largest accounting for just 21.9% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $4,274, 3.3 times the $1,284 reported in 2021. Among surgical clinicians in NY with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 497 payments — averaging $27.13 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$3K
- AstraZeneca$2K
- Novo Nordisk$2K
- Lilly USA, LLC$1K
- GSK$595
- Abbott$438
- plus $4K from 34 others
What the payments were for
- Food & beverage$13,484100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie | 106 | $2,958 |
| AstraZeneca | 55 | $2,306 |
| Novo Nordisk | 73 | $1,628 |
| Lilly USA, LLC | 55 | $1,236 |
| GSK | 30 | $595 |
| Abbott | 8 | $438 |
| Corcept Therapeutics | 31 | $437 |
| Bayer | 18 | $432 |
| Astellas Pharma US Inc | 15 | $381 |
| Janssen Scientific Affairs, LLC | 3 | $329 |
| Pfizer | 15 | $319 |
| Agile Therapeutics, Inc. | 9 | $318 |
| Madrigal Pharmaceuticals | 2 | $273 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 13 | $225 |
| Mayne Pharma Commercial LLC | 8 | $178 |
| Daiichi Sankyo Inc. | 7 | $165 |
| Johnson & Johnson | 2 | $154 |
| Boehringer Ingelheim | 6 | $146 |
| Almirall LLC | 1 | $121 |
| Idorsia Pharmaceuticals US Inc | 4 | $78 |
| Shield Therapeutics Inc | 2 | $77 |
| Avanir Pharmaceuticals, Inc. | 3 | $76 |
| Myovant Sciences Inc. | 4 | $69 |
| Exeltis, USA Inc. | 3 | $63 |
| Organon | 2 | $53 |
| Amarin Pharma, Inc. | 2 | $48 |
| Scynexis, Inc. | 2 | $47 |
| Otsuka America Pharmaceutical, Inc. | 2 | $42 |
| Lupin Inc. | 2 | $41 |
| Hologic Sales And Service, LLC | 2 | $38 |
| Ironshore Pharmaceuticals Inc. | 2 | $30 |
| Avion Pharmaceuticals | 2 | $29 |
| Mylan Pharmaceuticals Inc. | 1 | $27 |
| QOL Medical, LLC | 1 | $26 |
| Sanofi Pasteur Inc. | 1 | $24 |
| Merck | 1 | $23 |
| Dentsply IH Inc. | 1 | $18 |
| Ardelyx, Inc. | 1 | $14 |
| Therapeuticsmd, Inc. | 1 | $13 |
| Integra Lifesciences Corporation | 1 | $12 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$13,484 in reported general payments places this provider in the 95th percentile of 1,544 surgical providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 18 | $19,748 |
| VraylarCariprazine Hcl | 11 | $15,658 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 11 | $9,233 |
| SynthroidLevothyroxine Sodium | 18 | $2,268 |
| Rosuvastatin Calcium | 117 | $1,864 |
| Atorvastatin Calcium | 109 | $1,468 |
| Levothyroxine Sodium | 80 | $1,149 |
| Albuterol Sulfate HfaAlbuterol Sulfate | 29 | $1,105 |
| Famotidine | 24 | $899 |
| Pravastatin Sodium | 35 | $870 |
| Omeprazole | 70 | $808 |
| Amlodipine Besylate | 67 | $767 |
| Tamsulosin Hcl | 24 | $752 |
| Pantoprazole Sodium | 49 | $737 |
| Paroxetine Hcl | 27 | $702 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic | $1,628 | $19,74818 claims |
| AbbVieVraylar, Synthroid | $2,958 | $17,92629 claims |
| AstraZenecaBreztri Aerosphere | $2,306 | $9,23311 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 1,544 surgical providers in New York.
Other surgical in Brewster
- Lindsay SchweikarthAlbany$324K
- Nicole FeinNew York$225K
- Kenneth RuizNew York$93K
- Terry LinNew York$70K
- Beth PhillipsEast Syracuse$51K
- James DoolittleNew York$46K
- Tanya GeistAmherst$43K
- Irina KommNew York$39K
- Sarah MartineckWilliamsville$34K
- Richard DalabaAlbany$26K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.